- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00096135
Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia That Has Relapsed in the CNS or Testes
Treatment of Late Isolated Extramedullary Relapse From Acute Lymphoblastic Leukemia (ALL) (Initial CR1≥ 18 Months)
RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Giving combination chemotherapy together with radiation therapy may kill more cancer cells.
PURPOSE: This clinical trial is studying how well giving chemotherapy together with radiation therapy works in treating patients with acute lymphoblastic leukemia that has relapsed in the CNS and/or testes.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
- Legemiddel: terapeutisk hydrokortison
- Legemiddel: vinkristinsulfat
- Biologisk: filgrastim
- Legemiddel: cyclophosphamide
- Legemiddel: cytarabine
- Legemiddel: daunorubicin hydrochloride
- Legemiddel: dexamethasone
- Legemiddel: etoposide
- Legemiddel: leucovorin calcium
- Legemiddel: mercaptopurine
- Legemiddel: methotrexate
- Legemiddel: pegaspargase
- Stråling: radiation therapy
Detaljert beskrivelse
OBJECTIVES:
Primary
- Determine the efficacy of intensified systemic chemotherapy with reduced-dose CNS radiotherapy in patients with acute lymphoblastic leukemia and late isolated CNS relapse.
- Determine the efficacy of intensive systemic chemotherapy without testicular radiotherapy in patients with acute lymphoblastic leukemia and late isolated testicular relapse.
- Determine the toxicity of these regimens in these patients.
Secondary
- Determine whether bone marrow involvement is present at the time of extramedullary relapse in patients treated with these regimens.
- Correlate pretreatment minimal residual disease with outcomes in patients treated with these regimens.
- Correlate the role of host gene polymorphisms with toxicity of these regimens and incidence and outcome in these patients.
- Determine the neuropsychological sequelae associated with isolated CNS relapse and these treatment regimens in these patients.
OUTLINE: This is a pilot, multicenter study. All patients receive common induction, consolidation, re-induction, and intensification chemotherapy. Patients are stratified to maintenance therapy according to site of extramedullary relapse (CNS vs testicular).
- Induction therapy (weeks 1-4): Patients receive vincristine IV on days 1, 8, 15, and 22; oral dexamethasone twice daily on days 1-28; daunorubicin* IV over 15 minutes on days 1, 8, and 15; and intrathecal triple therapy** (ITT) comprising methotrexate, hydrocortisone, and cytarabine on days 1, 8, 15, and 22.
NOTE: *The total dose of anthracyclines on this study is capped at 450 mg/m2. Once this dose is reached, all subsequent doses of daunorubicin are omitted.
NOTE: **Patients with isolated testicular relapse receive ITT on day 1 only.
In addition to the above, patients with isolated testicular relapse also receive high-dose methotrexate IV continuously over 24 hours on day -14. Patients with clinical signs of disease at the end of induction undergo testicular biopsy.
Patients with CNS disease who do not achieve CNS remission after induction therapy receive additional ITT as above on days 29 and 36.
- Consolidation therapy (weeks 5-10): Patients receive high-dose cytarabine IV over 3 hours twice daily on days 1-2 and 22-23 and pegaspargase intramuscularly (IM) on days 2 and 23. Patients also receive filgrastim (G-CSF) subcutaneously (SC) beginning on days 3 and 24 and continuing until blood counts recover.
Patients with isolated testicular relapse with positive biopsy results at the end of induction undergo testicular radiotherapy once daily for a total of 12 fractions during consolidation therapy.
- Intensification I (weeks 11-22): Patients receive high-dose methotrexate with leucovorin calcium rescue IV over 24 hours on days 1, 22, 43, and 64 and oral mercaptopurine once daily on days 2-6, 23-27, 44-48, and 65-69. Patients also receive etoposide IV over 1 hour and cyclophosphamide IV over 15-30 minutes on days 8, 29, 50, and 71. Patients receive ITT* on days 15, 36, 57, and 78.
NOTE: *Patients with isolated testicular relapse receive ITT on days 36 and 78 only.
- Reinduction therapy (weeks 23-26): Patients receive vincristine IV on days 1, 8, 15, and 22; oral dexamethasone twice daily on days 1-7 and 15-21, and daunorubicin IV over 15 minutes on days 1, 8, and 15.
- Intensification II (weeks 27-50): Patients receive high-dose cytarabine IV over 3 hours twice daily on days 1-2, 43-44, 85-86, and 127-128; pegaspargase IM on days 2, 44, 86, and 128; ITT* on days 22, 64, 106, and 148; high-dose methotrexate IV continuously over 24 hours on days 29, 71, 113, and 155; oral mercaptopurine on days 30-34, 72-76, 114-118, and 156-160; and etoposide IV over 1 hour and cyclophosphamide IV over 15-30 minutes on days 36, 78, 120, and 162. Patients also receive G-CSF SC beginning on days 3, 45, 87, and 129 and continuing until blood counts recover.
NOTE: *Patients with isolated testicular relapse receive ITT on days 22 and 106 only.
- Chemotherapy and radiotherapy (weeks 51-54): Patients receive oral dexamethasone twice daily on days 1-7 and 15-21, vincristine IV on days 1, 8, and 15, and pegaspargase IM on days 1 and 15.
Patients with isolated CNS relapse also undergo cranial radiotherapy once daily, 5 days a week, for a total of 12 fractions.
- Maintenance therapy for isolated CNS relapse: (weeks 55-104): Patients receive dexamethasone PO orIV twice daily on days 1-5; oral mercaptopurine once daily on days 1-42; methotrexate IM on days 1, 8, 15, 22, 29, and 36; and vincristine IV and cyclophosphamide IV over 1 hour on days 43, 50, 57, and 64. Treatment repeats every 10 weeks for 5 courses.
Maintenance therapy for isolated testicular relapse:
- (Weeks 55-74): Patients receive ITT on day 1 and dexamethasone, mercaptopurine, methotrexate, vincristine, and cyclophosphamide as in maintenance therapy for isolated CNS relapse. Treatment repeats every 10 weeks for 2 courses.
- (Weeks 75-106): Patients receive vincristine IV on day 1; dexamethasone orally or IV on days 1-5; oral mercaptopurine on days 1-28; and methotrexate IM on days 1, 8, 15, and 22. Treatment repeats every 28 days for 8 courses. Patients also receive ITT on day 1 every 12 weeks for 3 doses.
Patients with combined testicular and CNS relapse receive high-dose methotrexate IV continuously over 24 hours on day -14 in addition to the same chemotherapy and radiotherapy administered during the induction, consolidation, intensification I, reinduction, intensification II, and maintenance phases of therapy as isolated CNS relapse patients.
All patients undergo neuropsychological assessment within 3 months after completion of induction therapy (before cranial radiotherapy) and at 2 years after completion of treatment.
Patients are followed for survival.
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
Western Australia
-
Perth, Western Australia, Australia, 6001
- Princess Margaret Hospital for Children
-
-
-
-
-
Quebec, Canada, G1V 4G2
- Centre Hospitalier Universitaire de Quebec
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 1Z2
- University of Alberta Hospital
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6H 3V4
- Children's & Women's Hospital of British Columbia
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3E 0V9
- CancerCare Manitoba
-
-
Newfoundland and Labrador
-
St. John's, Newfoundland and Labrador, Canada, A1B 3V6
- Janeway Children's Health and Rehabilitation Centre
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3J 3G9
- IWK Health Centre
-
-
Ontario
-
Hamilton, Ontario, Canada, L8N 3Z5
- McMaster Children's Hospital at Hamilton Health Sciences
-
Kingston, Ontario, Canada, K7L 2V7
- Cancer Centre of Southeastern Ontario at Kingston General Hospital
-
Ottawa, Ontario, Canada, K1H 8L1
- Children's Hospital of Eastern Ontario
-
-
Quebec
-
Montreal, Quebec, Canada, H3T 1C5
- Hôpital Sainte Justine
-
-
Saskatchewan
-
Regina, Saskatchewan, Canada, S4T 7T1
- Allan Blair Cancer Centre at Pasqua Hospital
-
Saskatoon, Saskatchewan, Canada, S7N 4H4
- Saskatoon Cancer Centre at the University of Saskatchewan
-
-
-
-
Alabama
-
Birmingham, Alabama, Forente stater, 35294
- UAB Comprehensive Cancer Center
-
-
Arizona
-
Phoenix, Arizona, Forente stater, 85016-7710
- Phoenix Children's Hospital
-
Tucson, Arizona, Forente stater, 85724-5024
- Arizona Cancer Center at University of Arizona Health Sciences Center
-
-
Arkansas
-
Little Rock, Arkansas, Forente stater, 72205
- Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
-
-
California
-
Downey, California, Forente stater, 90027
- Southern California Permanente Medical Group
-
Duarte, California, Forente stater, 91010-3000
- City of Hope Comprehensive Cancer Center
-
Loma Linda, California, Forente stater, 92354
- Loma Linda University Cancer Institute at Loma Linda University Medical Center
-
Long Beach, California, Forente stater, 90801
- Jonathan Jaques Children's Cancer Center at Miller Children's Hospital
-
Los Angeles, California, Forente stater, 90095-1781
- Jonsson Comprehensive Cancer Center at UCLA
-
Los Angeles, California, Forente stater, 90027
- Childrens Hospital Los Angeles
-
Madera, California, Forente stater, 93638-8762
- Children's Hospital Central California
-
Oakland, California, Forente stater, 94609
- Children's Hospital and Research Center Oakland
-
Orange, California, Forente stater, 92868
- Children's Hospital of Orange County
-
Palo Alto, California, Forente stater, 95798
- Lucile Packard Children's Hospital at Stanford University Medical Center
-
Sacramento, California, Forente stater, 95816
- Sutter Cancer Center
-
Sacramento, California, Forente stater, 95825
- Kaiser Permanente Medical Center - Oakland
-
San Francisco, California, Forente stater, 94115
- UCSF Helen Diller Family Comprehensive Cancer Center
-
-
Colorado
-
Aurora, Colorado, Forente stater, 80045
- Children's Hospital Center for Cancer and Blood Disorders
-
Denver, Colorado, Forente stater, 80218
- Presbyterian - St. Luke's Medical Center
-
-
Connecticut
-
Hartford, Connecticut, Forente stater, 06106
- Connecticut Children's Medical Center
-
-
Delaware
-
Wilmington, Delaware, Forente stater, 19803
- Alfred I. DuPont Hospital for Children
-
-
District of Columbia
-
Washington, District of Columbia, Forente stater, 20010-2970
- Children's National Medical Center
-
-
Florida
-
Fort Lauderdale, Florida, Forente stater, 33316
- Broward General Medical Center Cancer Center
-
Fort Myers, Florida, Forente stater, 33901
- Lee Cancer Care of Lee Memorial Health System
-
Gainesville, Florida, Forente stater, 32610-0232
- University of Florida Shands Cancer Center
-
Hollywood, Florida, Forente stater, 33021
- Memorial Cancer Institute at Memorial Regional Hospital
-
Jacksonville, Florida, Forente stater, 32207
- Nemours Children's Clinic
-
Miami, Florida, Forente stater, 33136
- University of Miami Sylvester Comprehensive Cancer Center - Miami
-
Miami, Florida, Forente stater, 33155
- Miami Children's Hospital
-
Miami, Florida, Forente stater, 33176
- Baptist-South Miami Regional Cancer Program
-
Orlando, Florida, Forente stater, 32803-1273
- Florida Hospital Cancer Institute at Florida Hospital Orlando
-
Orlando, Florida, Forente stater, 32806
- Nemours Children's Clinic - Orlando
-
Orlando, Florida, Forente stater, 32806
- M.D. Anderson Cancer Center at Orlando
-
Pensacola, Florida, Forente stater, 32504
- Sacred Heart Cancer Center at Sacred Heart Hospital
-
Saint Petersburg, Florida, Forente stater, 33701
- All Children's Hospital
-
Tampa, Florida, Forente stater, 33607
- St. Joseph's Cancer Institute at St. Joseph's Hospital
-
West Palm Beach, Florida, Forente stater, 33407
- Kaplan Cancer Center at St. Mary's Medical Center
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30322
- AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus
-
-
Hawaii
-
Honolulu, Hawaii, Forente stater, 96813
- Cancer Research Center of Hawaii
-
-
Idaho
-
Boise, Idaho, Forente stater, 83712-6297
- Mountain States Tumor Institute at St. Luke's Regional Medical Center
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60612-7243
- University of Illinois Cancer Center
-
Maywood, Illinois, Forente stater, 60153
- Cardinal Bernardin Cancer Center at Loyola University Medical Center
-
Oak Lawn, Illinois, Forente stater, 60453
- Keyser Family Cancer Center at Advocate Hope Children's Hospital
-
Park Ridge, Illinois, Forente stater, 60068-1174
- Advocate Lutheran General Cancer Care Center
-
Springfield, Illinois, Forente stater, 62794-9677
- Simmons Cooper Cancer Institute
-
-
Indiana
-
Indianapolis, Indiana, Forente stater, 46202-5289
- Indiana University Melvin and Bren Simon Cancer Center
-
Indianapolis, Indiana, Forente stater, 46260
- St. Vincent Indianapolis Hospital
-
-
Iowa
-
Des Moines, Iowa, Forente stater, 50309
- Blank Children's Hospital
-
Iowa City, Iowa, Forente stater, 52242-1002
- Holden Comprehensive Cancer Center at University of Iowa
-
-
Kansas
-
Kansas City, Kansas, Forente stater, 66160-7357
- Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center
-
-
Kentucky
-
Lexington, Kentucky, Forente stater, 40536-0093
- Lucille P. Markey Cancer Center at University of Kentucky
-
Louisville, Kentucky, Forente stater, 40232
- Kosair Children's Hospital
-
-
Maine
-
Bangor, Maine, Forente stater, 04401
- CancerCare of Maine at Eastern Maine Medical Center
-
-
Maryland
-
Baltimore, Maryland, Forente stater, 21215
- Alvin and Lois Lapidus Cancer Institute at Sinai Hospital
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02111
- Floating Hospital for Children at Tufts - New England Medical Center
-
-
Michigan
-
Ann Arbor, Michigan, Forente stater, 48109-0286
- C.S. Mott Children's Hospital at University of Michigan Medical Center
-
Detroit, Michigan, Forente stater, 48201-1379
- Barbara Ann Karmanos Cancer Institute
-
Flint, Michigan, Forente stater, 48503
- Hurley Medical Center
-
Grand Rapids, Michigan, Forente stater, 49503-2560
- Butterworth Hospital at Spectrum Health
-
Grosse Pointe Woods, Michigan, Forente stater, 48236
- Van Elslander Cancer Center at St. John Hospital and Medical Center
-
Kalamazoo, Michigan, Forente stater, 49007-5381
- CCOP - Kalamazoo
-
Lansing, Michigan, Forente stater, 48910
- Breslin Cancer Center at Ingham Regional Medical Center
-
-
Minnesota
-
Minneapolis, Minnesota, Forente stater, 55404
- Children's Hospitals and Clinics of Minnesota - Minneapolis
-
Rochester, Minnesota, Forente stater, 55905
- Mayo Clinic Cancer Center
-
-
Mississippi
-
Jackson, Mississippi, Forente stater, 39216-4505
- University of Mississippi Cancer Clinic
-
-
Missouri
-
Columbia, Missouri, Forente stater, 65203
- Ellis Fischel Cancer Center at University of Missouri - Columbia
-
Kansas City, Missouri, Forente stater, 64108
- Children's Mercy Hospital
-
-
Nevada
-
Las Vegas, Nevada, Forente stater, 89109-2306
- CCOP - Nevada Cancer Research Foundation
-
-
New Hampshire
-
Lebanon, New Hampshire, Forente stater, 03756-0002
- Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center
-
-
New Jersey
-
Hackensack, New Jersey, Forente stater, 07601
- Hackensack University Medical Center Cancer Center
-
Morristown, New Jersey, Forente stater, 07962
- Overlook Hospital
-
New Brunswick, New Jersey, Forente stater, 08901
- Saint Peter's University Hospital
-
New Brunswick, New Jersey, Forente stater, 08903
- Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School
-
Newark, New Jersey, Forente stater, 07112
- Newark Beth Israel Medical Center
-
Paterson, New Jersey, Forente stater, 07503
- St. Joseph's Hospital and Medical Center
-
-
New Mexico
-
Albuquerque, New Mexico, Forente stater, 87131-5636
- University of New Mexico Cancer Center
-
-
New York
-
Bronx, New York, Forente stater, 10461
- Albert Einstein Cancer Center at Albert Einstein College of Medicine
-
Brooklyn, New York, Forente stater, 11201-5493
- Brooklyn Hospital Center
-
Brooklyn, New York, Forente stater, 11219
- Maimonides Cancer Center at Maimonides Medical Center
-
Buffalo, New York, Forente stater, 14263-0001
- Roswell Park Cancer Institute
-
Mineola, New York, Forente stater, 11501
- Winthrop University Hospital
-
New Hyde Park, New York, Forente stater, 11040
- Schneider Children's Hospital
-
New York, New York, Forente stater, 10016
- NYU Cancer Institute at New York University Medical Center
-
New York, New York, Forente stater, 10032
- Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center
-
Rochester, New York, Forente stater, 14642
- James P. Wilmot Cancer Center at University of Rochester Medical Center
-
Stony Brook, New York, Forente stater, 11794-9446
- Stony Brook University Cancer Center
-
Syracuse, New York, Forente stater, 13210
- SUNY Upstate Medical University Hospital
-
Valhalla, New York, Forente stater, 10595
- New York Medical College
-
-
North Carolina
-
Charlotte, North Carolina, Forente stater, 28232-2861
- Blumenthal Cancer Center at Carolinas Medical Center
-
Charlotte, North Carolina, Forente stater, 28233-3549
- Presbyterian Cancer Center at Presbyterian Hospital
-
Durham, North Carolina, Forente stater, 27710
- Duke Comprehensive Cancer Center
-
Winston-Salem, North Carolina, Forente stater, 27157-1096
- Wake Forest University Comprehensive Cancer Center
-
-
North Dakota
-
Fargo, North Dakota, Forente stater, 58122
- CCOP - MeritCare Hospital
-
-
Ohio
-
Akron, Ohio, Forente stater, 44308-1062
- Akron Children's Hospital
-
Cleveland, Ohio, Forente stater, 44195
- Cleveland Clinic Taussig Cancer Center
-
Cleveland, Ohio, Forente stater, 44106-5000
- Rainbow Babies and Children's Hospital
-
Columbus, Ohio, Forente stater, 43205-2696
- Nationwide Children's Hospital
-
Dayton, Ohio, Forente stater, 45404-1815
- Dayton Children's - Dayton
-
Toledo, Ohio, Forente stater, 43614
- Medical University of Ohio Cancer Center
-
Youngstown, Ohio, Forente stater, 44501
- Tod Children's Hospital
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forente stater, 73104
- Oklahoma University Cancer Institute
-
-
Oregon
-
Portland, Oregon, Forente stater, 97239-3098
- Knight Cancer Institute at Oregon Health and Science University
-
Portland, Oregon, Forente stater, 97227
- Legacy Emanuel Hospital and Health Center and Children's Hospital
-
-
Pennsylvania
-
Bethlehem, Pennsylvania, Forente stater, 18017
- Lehigh Valley Hospital - Muhlenberg
-
Danville, Pennsylvania, Forente stater, 17822-0001
- Geisinger Cancer Institute at Geisinger Health
-
Hershey, Pennsylvania, Forente stater, 17033-0850
- Penn State Children's Hospital
-
Philadelphia, Pennsylvania, Forente stater, 19134-1095
- St. Christopher's Hospital for Children
-
Philadelphia, Pennsylvania, Forente stater, 19104-9786
- Children's Hospital of Philadelphia
-
Pittsburgh, Pennsylvania, Forente stater, 15213
- Children's Hospital of Pittsburgh of UPMC
-
-
Rhode Island
-
Providence, Rhode Island, Forente stater, 02903
- Rhode Island Hospital Comprehensive Cancer Center
-
-
South Carolina
-
Charleston, South Carolina, Forente stater, 29425
- Hollings Cancer Center at Medical University of South Carolina
-
Greenville, South Carolina, Forente stater, 29605
- Greenville Hospital Cancer Center
-
-
South Dakota
-
Sioux Falls, South Dakota, Forente stater, 57117-5039
- Sanford Cancer Center at Sanford USD Medical Center
-
-
Tennessee
-
Chattanooga, Tennessee, Forente stater, 37403
- T.C. Thompson Children's Hospital
-
Knoxville, Tennessee, Forente stater, 37901
- East Tennessee Children's Hospital
-
Nashville, Tennessee, Forente stater, 37232-6838
- Vanderbilt-Ingram Cancer Center
-
-
Texas
-
Amarillo, Texas, Forente stater, 79106
- Texas Tech University Health Sciences Center School of Medicine - Amarillo
-
Corpus Christi, Texas, Forente stater, 78411
- Driscoll Children's Hospital
-
Dallas, Texas, Forente stater, 75230
- Medical City Dallas Hospital
-
Dallas, Texas, Forente stater, 75390
- Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas
-
Fort Worth, Texas, Forente stater, 76104
- Cook Children's Medical Center - Fort Worth
-
Houston, Texas, Forente stater, 77030-2399
- Baylor University Medical Center - Houston
-
San Antonio, Texas, Forente stater, 78229-3993
- Methodist Children's Hospital of South Texas
-
San Antonio, Texas, Forente stater, 78207
- University of Texas Health Science Center at San Antonio
-
-
Utah
-
Salt Lake City, Utah, Forente stater, 84113-1100
- Primary Children's Medical Center
-
-
Vermont
-
Burlington, Vermont, Forente stater, 05401
- Fletcher Allen Health Care - University Health Center Campus
-
-
Virginia
-
Falls Church, Virginia, Forente stater, 22042-3300
- INOVA Fairfax Hospital
-
Roanoke, Virginia, Forente stater, 24014
- Carilion Medical Center for Children at Roanoke Community Hospital
-
-
Washington
-
Spokane, Washington, Forente stater, 99220-2555
- Providence Cancer Center at Sacred Heart Medical Center
-
-
West Virginia
-
Charleston, West Virginia, Forente stater, 25302
- West Virginia University Health Sciences Center - Charleston
-
Morgantown, West Virginia, Forente stater, 26506
- Mary Babb Randolph Cancer Center at West Virginia University Hospitals
-
-
Wisconsin
-
Green Bay, Wisconsin, Forente stater, 54307-3508
- St. Vincent Hospital Regional Cancer Center
-
La Crosse, Wisconsin, Forente stater, 54601
- Gundersen Lutheran Center for Cancer and Blood
-
Marshfield, Wisconsin, Forente stater, 54449
- Marshfield Clinic - Marshfield Center
-
Milwaukee, Wisconsin, Forente stater, 53226
- Midwest Children's Cancer Center at Children's Hospital of Wisconsin
-
-
-
-
-
Auckland, New Zealand, 1
- Starship Children's Health
-
Christchurch, New Zealand, 8140
- Christchurch Hospital
-
-
-
-
-
Bern, Sveits, 3010
- Swiss Pediatric Oncology Group Bern
-
Geneva, Sveits, 1205
- Swiss Pediatric Oncology Group Geneva
-
Lausanne, Sveits, 1011
- Swiss Pediatric Oncology Group Lausanne
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
DISEASE CHARACTERISTICS:
Diagnosis of acute lymphoblastic leukemia (ALL)
- B-precursor lineage (T-precursor lineage closed to accrual as of 05/20/10)
- In first bone marrow remission (M1 by morphology) AND duration of first complete remission ≥ 18 months from time of initial diagnosis
First isolated CNS and/or testicular relapse
Isolated CNS relapse, as defined by 1 of the following:
- WBC ≥ 5/mm^3 in cerebrospinal fluid (CSF) with blasts present on cytospin
Any number of WBC in CSF with immunophenotypic proof of leukemic relapse, defined by the following:
Identifiable blasts AND 1 of the following:
- B-lineage (TdT OR CD-10-positive on 2 consecutive CSF samples obtained 4 weeks apart)
- T-lineage (TdT AND CD-7 OR TdT positivity alone on 2 consecutive CSF samples obtained 4 weeks apart) (Closed to accrual as of 05/20/10)
- Isolated testicular relapse, defined as biopsy proven testicular involvement
- No Down syndrome
- No T-cell ALL or T-cell non-Hodgkin lymphoma
- No known optic nerve and/or retinal involvement
PATIENT CHARACTERISTICS:
Age
- 18 months to 29 years at relapse
Performance status
- Karnofsky 30-100% (for patients > 16 years of age) OR
- Lansky 30-100% (for patients ≤ 16 years of age)
Life expectancy
- Not specified
Hematopoietic
- Not specified
Hepatic
- Not specified
Renal
Creatinine adjusted according to age as follows:
- No greater than 0.4 mg/dL (≤ 5 months)
- No greater than 0.5 mg/dL (6 months -11 months)
- No greater than 0.6 mg/dL (1 year-23 months)
- No greater than 0.8 mg/dL (2 years-5 years)
- No greater than 1.0 mg/dL (6 years-9 years)
- No greater than 1.2 mg/dL (10 years-12 years)
- No greater than 1.4 mg/dL (13 years and over [female])
- No greater than 1.5 mg/dL (13 years to 15 years [male])
- No greater than 1.7 mg/dL (16 years and over [male]) OR
- Creatinine clearance or radioisotope glomerular filtration rate at least 70 mL/min
Cardiovascular
- Shortening fraction ≥ 27% by echocardiogram OR
- Ejection fraction ≥ 50% by MUGA
Other
- Not pregnant or nursing
PRIOR CONCURRENT THERAPY:
Biologic therapy
- No prior bone marrow transplantation
Chemotherapy
- Prior total anthracycline dosage ≤ 360 mg/m^2
Endocrine therapy
- Not specified
Radiotherapy
- Not specified
Surgery
- Not specified
Other
- No prior systemic therapy for concurrent extramedullary relapse
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: CNS Patients-Treatment (combination chemotherapy)
All patients receive common induction (vincristine sulfate, dexamethasone, daunorubicin hydrochloride & intrathecal triple therapy (ITT: MTX, therapeutic hydrocortisone and cytarabine)), consolidation (cytarabine, pegaspargase, filgrastim, re-induction (vincristine, dexamethasone, daunorubicin), and intensification chemotherapy (MTX, leucovorin calcium, mercaptopurine, etoposide, cyclophosphamide & ITT.
|
gitt IV
Andre navn:
given subcutaneously (SC)
Andre navn:
IV over 15-30 minutes
Andre navn:
IV over 3 hours twice daily
Andre navn:
IV over 15 minutes
Andre navn:
oral twice daily
Andre navn:
IV over 1 hour
Andre navn:
rescue IV over 24 hours
Andre navn:
oral
Andre navn:
intramuscularly (IM)
Andre navn:
intramuscularly (IM)
Andre navn:
Patients with isolated testicular relapse will start Induction with a single dose of high-dose methotrexate (HDMTX) and will not receive either testicular or cranial radiation.
Patients with isolated CNS relapse will NOT receive the initial dose of HDMTX prior to Induction, but will receive 1200 cGy of cranial radiation after completing the initial 12 months of intensive systemic chemotherapy.
|
|
Eksperimentell: Testicular Relapse Patients (Combination chemotherapy)
All patients receive common induction (vincristine sulfate, dexamethasone, daunorubicin hydrochloride & intrathecal triple therapy (ITT: MTX, therapeutic hydrocortisone and cytarabine)), consolidation (cytarabine, pegaspargase, filgrastim, testicular radiation therapy, re-induction (vincristine, dexamethasone, daunorubicin), and intensification chemotherapy (MTX, leucovorin calcium, mercaptopurine, etoposide, cyclophosphamide & ITT.
|
gitt IV
Andre navn:
given subcutaneously (SC)
Andre navn:
IV over 15-30 minutes
Andre navn:
IV over 3 hours twice daily
Andre navn:
IV over 15 minutes
Andre navn:
oral twice daily
Andre navn:
IV over 1 hour
Andre navn:
rescue IV over 24 hours
Andre navn:
oral
Andre navn:
intramuscularly (IM)
Andre navn:
intramuscularly (IM)
Andre navn:
Patients with isolated testicular relapse will start Induction with a single dose of high-dose methotrexate (HDMTX) and will not receive either testicular or cranial radiation.
Patients with isolated CNS relapse will NOT receive the initial dose of HDMTX prior to Induction, but will receive 1200 cGy of cranial radiation after completing the initial 12 months of intensive systemic chemotherapy.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Event-free Survival
Tidsramme: 3 years
|
Monitoring of efficacy results will be performed in comparison with historical results.
|
3 years
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Studiestol: Julio C. Barredo, MD, University of Miami Miller School of Medicine-Sylvester Cancer Center
- Studiestol: Caroline A. Hastings, MD, UCSF Benioff Children's Hospital Oakland
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Sykdommer i immunsystemet
- Neoplasmer etter histologisk type
- Neoplasmer
- Lymfoproliferative lidelser
- Lymfesykdommer
- Immunproliferative lidelser
- Leukemi
- Forløpercelle lymfoblastisk leukemi-lymfom
- Leukemi, lymfoid
- Fysiologiske effekter av legemidler
- Molekylære mekanismer for farmakologisk virkning
- Anti-infeksjonsmidler
- Autonome agenter
- Agenter fra det perifere nervesystemet
- Antivirale midler
- Nukleinsyresyntesehemmere
- Enzymhemmere
- Anti-inflammatoriske midler
- Antirevmatiske midler
- Antimetabolitter, antineoplastisk
- Antimetabolitter
- Antineoplastiske midler
- Immunsuppressive midler
- Immunologiske faktorer
- Tubulin modulatorer
- Antimitotiske midler
- Mitosemodulatorer
- Antiemetika
- Gastrointestinale midler
- Glukokortikoider
- Hormoner
- Hormoner, hormonsubstitutter og hormonantagonister
- Antineoplastiske midler, hormonelle
- Beskyttende agenter
- Antineoplastiske midler, Alkylering
- Alkyleringsmidler
- Myeloablative agonister
- Antineoplastiske midler, fytogene
- Topoisomerase II-hemmere
- Topoisomerasehemmere
- Dermatologiske midler
- Mikronæringsstoffer
- Adjuvanser, immunologiske
- Antibiotika, antineoplastisk
- Vitaminer
- Reproduktive kontrollmidler
- Motgift
- Vitamin B kompleks
- Abortfremkallende midler, ikke-steroide
- Aborterende midler
- Folsyreantagonister
- Deksametason
- Cyklofosfamid
- Etoposid
- Leucovorin
- Levoleucovorin
- Lenograstim
- Cytarabin
- Metotreksat
- Vincristine
- Daunorubicin
- Asparaginase
- Merkaptopurin
- Hydrokortison
- Hydrokortison 17-butyrat 21-propionat
- Hydrokortisonacetat
- Hydrokortison hemisuksinat
- Pegaspargase
Andre studie-ID-numre
- AALL02P2
- COG-AALL02P2 (Annen identifikator: Children's Oncology Group)
- NCI-2011-01623 (Annen identifikator: NCI Trial Identifier)
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .